Ofloxacin-Ophtal® Sine (Ofloxacin)

Ofloxacin belongs to the fluoroquinolone class and works by inhibiting bacterial DNA gyrase and topoisomerase IV. These enzymes are essential for DNA replication and transcription. By blocking them, Ofloxacin prevents bacterial cell division, leading to bacterial death and clearance of the infection.

The specific dosing regimen for Ofloxacin‑Ophtal® Sine is determined by the prescribing clinician based on the type and severity of the infection, patient age and response to therapy. The prescriber will indicate the number of drops and frequency appropriate for each case.

Safety data for topical Ofloxacin in pregnancy and lactation are limited. It should be used only when the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician after a thorough risk‑benefit assessment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including any cold‑chain requirements) and assists with import documentation.

Ofloxacin offers broad‑spectrum activity against Gram‑negative and many Gram‑positive ocular pathogens, similar to other fluoroquinolones such as ciprofloxacin. Compared with older agents like chloramphenicol, Ofloxacin generally provides higher potency and a lower risk of resistance, but the choice depends on local susceptibility patterns and physician preference.

Store the ocular solution at room temperature, below 25 °C, in its original container. Protect it from direct sunlight and moisture. Keep the bottle tightly closed when not in use and discard any solution that appears discolored or contaminated.

The solution is applied topically to the affected eye(s). The prescriber will advise the number of drops per dose and the frequency (e.g., one drop every 2‑4 hours). Patients should wash their hands before and after instillation and avoid touching the tip of the bottle to the eye or any surface.

Serious adverse events, although rare, include corneal ulceration, severe allergic reactions such as anaphylaxis, and systemic hypersensitivity syndromes like Stevens‑Johnson syndrome. Any sudden loss of vision, intense eye pain, or signs of a severe allergic reaction require immediate medical attention.

Patients with a known hypersensitivity to Ofloxacin, other fluoroquinolones, or any excipients in the formulation should avoid this product. It is also contraindicated in individuals with a history of tendon disorders related to fluoroquinolone use, and it should be used with caution in patients with pre‑existing corneal disease.